Atlas Trials

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)

Clinical trial NCT07366034 · RECRUITING

Trial details

NCT number
NCT07366034
Sponsor
Boehringer Ingelheim
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Fibrosing Interstitial Lung Disease
Start date
2026-07-21
Primary completion
2029-04-27
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.